In a research note, Deutsche Bank analyst Jan Koch has maintained his recommendation on the stock with a Buy rating. The target price remains unchanged at CHF 110.
DocMorris AG
/ Key word: Quarterly / Interim Statement
DocMorris continues to grow in the first quarter of 2024 and creates digital access to the entire e-prescription market...
Analyst Alexander Thiel from Jefferies research considers the stock attractive and recommends it with a Buy rating. The target price has been revised upwards and is now set at CHF 110, compared with...
DocMorris AG / Key word: Market Launch
DocMorris AG: DocMorris receives gematik approval for simple digital e-prescription redemption via health card
10-Apr-2024 / 07:00...
DocMorris AG / Key word: Annual Results
DocMorris AG: Significant earnings improvement in 2023; e-prescription is standard in Germany
21-March-2024 / 06:58 CET/CEST
Release of an ad hoc...
In a research note, Jefferies analyst Martin Comtesse has maintained his recommendation on the stock with a Buy rating. The target price remains unchanged at CHF 90.
/PRNewswire/ -- According to Technavio, the pharma e-commerce market size in Europe is estimated to grow by USD 16.42 billion from 2022 to 2027. The market is...
/PRNewswire/ -- The latest market research report, "Pharma E-Commerce Market in Europe by Product and Geography - Forecast and Analysis" by Technavio infers...
/PRNewswire/ -- The latest pharma e-commerce market research report in Europe by Technavio indicates that the availability of secure internet facilities in...
EQS Group-News: Zur Rose Group AG / Mot-clé : Résultat annuel
Le groupe Zur Rose consolide sa position de leader sur le marché européen et lance avec succès sa plateforme de santé
2021-03-18 /... | March 18, 2021
Bank of America has predicted a "big bang" for the European e-pharmacy sector and named stocks they think will outperform, even if Amazon enters the market.